LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

2,569
Loading...
Loading...
Upcoming Earnings: Q3 '25
Reports: Nov 06,
Pre-Market

Estimated EPS

$1.92

Estimated Rev

$58.64M

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '25
$1.92
--
--
N/A
Q2 '25
$1.42
$1.60
12.56%
BEAT
Q1 '25
$1.21
$1.33
9.77%
BEAT
Q4 '24
$1.16
$1.27
9.67%
BEAT
Q3 '24
$1.35
$1.84
36.59%
BEAT

Latest LGND News

View

Advertisement|Remove ads.

Advertisement|Remove ads.